Literature DB >> 2243677

Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy.

C M Mooy1, P T de Jong, T H Van der Kwast, P G Mulder, M J Jager, D J Ruiter.   

Abstract

The reactivity of 33 choroidal and ciliary body melanomas with monoclonal antibody Ki-67, which recognizes a proliferation associated nuclear antigen, has been assessed and compared with clinicopathologic parameters. In 23 cases, 8 Gy irradiation was given 2 days before enucleation. Nonirradiated melanomas had a significantly higher proliferation rate as defined by staining with monoclonal antibody Ki-67 as compared with irradiated tumors (P = 0.007). Similarly, a strong relationship was found between pre-enucleation irradiation and low mitotic activity (P = 0.001). There was no significant correlation between the presence of Ki-67-positive nuclei and histologic classification, largest tumor diameter, localization of the tumor, age, sex, scleral invasion, pigmentation, and lymphocytic infiltration. The relevance of Ki-67 immunohistochemistry for the assessment of the life prognosis of patients with uveal melanoma has to be studied prospectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2243677     DOI: 10.1016/s0161-6420(90)32420-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

1.  Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas.

Authors:  C Chiquet; J D Grange; L Ayzac; P Chauvel; L M Patricot; M Devouassoux-Shisheboran
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  Comparison of immunostainings for proliferating cell nuclear antigen and Ki-67 in human extraocular lesions.

Authors:  T Kodama; K Kawamoto; T Kono; Y Shibuya; T Setogawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-12       Impact factor: 3.117

3.  Association between gene expression profile, proliferation and metastasis in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; J William Harbour
Journal:  Curr Eye Res       Date:  2010-09       Impact factor: 2.424

4.  Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma.

Authors:  S E Coupland; N Bechrakis; A Schüler; I Anagnostopoulos; M Hummel; N Bornfeld; H Stein
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

5.  DNA flow cytometry in uveal melanoma: the effect of pre-enucleation irradiation.

Authors:  C Mooy; K Vissers; G Luyten; A Mulder; T Stijnen; P de Jong; F Bosman
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

6.  Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma.

Authors:  C M Mooy; G P Luyten; P T de Jong; T M Luider; T Stijnen; F van de Ham; C C van Vroonhoven; F T Bosman
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

7.  MIB-1 and PC-10 immunostaining for the assessment of proliferative activity in primary acquired melanosis without and with atypia.

Authors:  I Chowers; N Livni; A Solomon; G Zajicek; J Frucht-Pery; R Folberg; J Pe'er
Journal:  Br J Ophthalmol       Date:  1998-11       Impact factor: 4.638

8.  Extrascleral Tumor Extension Associated with Localized Scleral Melt following Plaque Brachytherapy for Uveal Melanoma: Clinical and Histologic Findings.

Authors:  Chau M Pham; Steven M Couch; George J Harocopos
Journal:  Ocul Oncol Pathol       Date:  2017-08-23

9.  Overexpression of high mobility group A1 protein in human uveal melanomas: implication for prognosis.

Authors:  Yi Qu; Yupeng Wang; Jinlan Ma; Yue Zhang; Nana Meng; Hao Li; Yan Wang; Wenbin Wei
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

10.  The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival.

Authors:  Shanna Dewaele; Louis Delhaye; Boel De Paepe; Eric James de Bony; Jilke De Wilde; Katrien Vanderheyden; Jasper Anckaert; Nurten Yigit; Justine Nuytens; Eveline Vanden Eynde; Joél Smet; Maxime Verschoore; Fariba Nemati; Didier Decaudin; Manuel Rodrigues; Peihua Zhao; Aart Jochemsen; Eleonora Leucci; Jo Vandesompele; Jo Van Dorpe; Jean-Christophe Marine; Rudy Van Coster; Sven Eyckerman; Pieter Mestdagh
Journal:  Oncogene       Date:  2021-09-10       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.